Info

Astralis Ltd. (Astralis) is a development-stage biotechnology company that was engaged primarily in the research and development of treatments for immune system disorders and skin diseases, such as psoriasis and psoriatic and rheumatoid arthritis. The Company's initial product candidate, Psoraxine, is a protein extract used for the treatment of the skin disease psoriasis. The Company has one product in clinical development, and has pre-clinical focus in areas, including eczema, rheumatoid arthritis and leishmaniasis. Psoraxine, for the treatment of moderate to severe psoriasis, is in Phase II clinical trials.